anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To assess asymptomatic rates and severity of SARS-CoV-2 infection in people with epilepsy and their healthcare workers in a long-term care facility which had implemented weekly surveillance testing between April 2020 and June 2022.
METHODS: Questionnaires focused on objective and subjective COVID-19 symptoms for people with epilepsy residing in and their healthcare workers at the Chalfont Centre for Epilepsy in June 2022. Demographic information, comorbidities, and seizure frequency were gathered from medical records. We also collected responses on objective and subjective COVID-19 symptoms from healthcare workers who participated in a prospective study assessing the reaction to COVID-19 vaccinations (SAFER).
RESULTS: Fifty-five out of 89 (62%) residents tested positive at least once on weekly PCR testing for SARS-CoV-2 during the period of interest; 20 of those (37%) were asymptomatic. In comparison, of those 63 healthcare workers who tested positive at least once on weekly testing during the same period, only four (6%) were asymptomatic. Of the 159 healthcare workers who also participated in the SAFER study, 41 tested positive at least once, and seven (17%) were completely asymptomatic during infection with SARS-CoV-2.
SIGNIFICANCE: People with epilepsy living in a long-term care facility were more likely to present with asymptomatic SARS-CoV-2 infections than healthcare workers at the same facility. Despite possible bias in the reporting of subjective symptoms due to management-by-proxy, there is no evidence that vulnerable people living in an epilepsy long-term care facility showed reduced resilience towards infections.
PLAIN LANGUAGE SUMMARY: People with epilepsy living in care home facilities had a surprisingly high degree of asymptomatic infections with SARS-CoV-2. Very few residents had severe or fatal outcomes. This is in stark contrast to the widely reported bad outcomes for people without epilepsy in other care homes. People with epilepsy reported significantly less symptoms than their healthcare workers. No changes in seizure frequency during or after infection were observed.
The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. 
     The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.
The invention discloses a hand washing skincare capsule. The capsule comprises a liquid soap capsule and a skincare liquid capsule. The liquid soap capsule comprises a capsule body (A) filled with liquid soap and a cover (A), and the capsule body (A) and the cover (A) are connected through threads. The skincare liquid capsule comprises a capsule body (B) filled with skincare liquid and a cover (B), and the capsule body (B) and the cover (B) are connected through threads. One end of the cover (A) and one end of the cover (B) are both concaved so as to form a recessed groove (A) and a recessed groove (B) respectively; the size of the groove (A) and the size of the groove (B) are identical, the recessed groove (A) and the recessed groove (B) are connected through threads, a cavity is formed, tissues are placed in the cavity, and the hand washing skincare capsule is made of polycaprolactone. The hand washing skincare capsule has the advantages that after hand washing, tissues can be taken out to wipe the hands, the hand washing and skin caring can be performed at the same time, and the whole capsule is made of biodegradable materials, and thus is environment-friendly.
Macrophages, as highly heterogeneous and plastic immune cells, occupy a pivotal role in both pro‑inflammatory (M1) and anti‑inflammatory (M2) responses. While M1‑type macrophages secrete pro‑inflammatory factors to initiate and sustain inflammation, M2‑type macrophages promote inflammation regression and uphold tissue homeostasis. These distinct phenotypic transitions in macrophages are closely linked to significant alterations in cellular metabolism, encompassing key response pathways such as glycolysis, pentose phosphate pathway, oxidative phosphorylation, lipid metabolism, amino acid metabolism, the tricarboxylic acid cycle and iron metabolism. These metabolic adaptations enable macrophages to adapt their activities in response to varying disease microenvironments. Therefore, the present review focused primarily on elucidating the intricate metabolic pathways that underlie macrophage functionality. Subsequently, it offers a comprehensive overview of the current state‑of‑the‑art nanomaterials, highlighting their promising potential in modulating macrophage metabolism to effectively hinder disease progression in both cancer and atherosclerosis.
The invention discloses a molecule for targeting the specific receptors in mitigating breast cancer and prostate cancer. The magic bullet is derived as a small molecule using the molecular modelling technique. The molecule of formula (I) comprises the acid as first chemical moiety, hormone derivative as second chemical moiety and the anticancer agent as third chemical moiety. The acid is citric acid or tartaric acid. The hormone for the molecule of formula (I) is estradiol, genistein, apigenin or dihydroxy testosterone. The drug used is selected from 5-flurouracil, capecitabine, gemcitabine, 6-mercaptopurine or calibridin for treatment of breast cancer and 5-flurouracil for treatment of prostate cancer. The molecule of formula (I) is chemically stable, cost effective, exhibits improved efficacy due to specific target, extended duration of therapeutic activity without inducing any immune reaction.
PROBLEM TO BE SOLVED: To efficiently obtain cinnamamide useful as a sedative/anesthetic for fish or a stabilizer for halogen-contg. resins, by culturing cinnamamide- productive bacteria belonging to Streptoverticillium followed by collecting the aimed product from the cultured product. SOLUTION: Cinnamamide-productive bacteria belonging to Streptoverticillium [e.g. Streptoverticillium sp.A-1143 strain (JCM No.4438)] is inoculated upon a medium and subjected to shaking culture at 28 deg.C for 2 days to prepare seeds, which is then cultured at 28 deg.C for 5 days under an aeration of 50L/min and agitation of 110rpm. The resultant culture fluid is then subjected to centrifugation and separated into microbes and a supernatant, and the supernatant is filtered and the filtrate is put through an adsorptive resin column. Subsequently, the adsorbed product is eluted with 80% methanol, the resultant elute is subjected to extraction with toluene, and the resultant extract is concentrated and then subjected to column chromatography, thus obtaining the objective cinnamamide.
The utility model relates to a medical appliance, which is a moxibustion plaster. The moxibustion plaster is a rectangle, and the internal layer of the cross sectional shape of the moxibustion plaster is a protective layer. A layer of oxide is on the protective layer, a bonding layer is on the layer of oxide, the bonding layer is provided with a magnetic sheet, and the bonding layer is also provided with a far infrared layer. The two ends of the rectangle are respectively provided with an arc protecting wing. The layer of oxide is a plastic foil bag in which exothermic materials are arranged. The exothermic materials are composed of ferrous powder, common salt, water absorbing resin, carbon powder, crushed crude pearlite and water. The designing goal of the utility model is to provide a moxibustion plaster which can adopt exothermic materials to generate temperature, and can simultaneously apply magnetotherapy and far infrared combined together, achieving the goals of relaxing muscles and tendons to promote blood circulation, easing pain, diminishing inflammation, etc.
BACKGROUND: Arteriovenous grafts (AVGs) are used for patients deemed unsuitable for the creation of an autogenous arteriovenous fistula (AVF) or unable to await maturation of the AVF before starting hemodialysis. However, AVGs are prone to infection and thrombosis resulting in low long-term patency rates. The novel aXess Hemodialysis Graft consists of porous polymeric biomaterial allowing the infiltration by cells and the growth of neotissue, while the graft itself is gradually absorbed, ultimately resulting in a fully functional natural blood vessel. The Pivotal Study will examine the long-term effectiveness and safety of the aXess Hemodialysis Graft.
METHODS: The Pivotal Study is a prospective, single-arm, multicenter study that will be conducted in 110 subjects with end-stage renal disease who are not deemed suitable for the creation of an autogenous vascular access. The primary efficacy endpoint will be the primary patency rate at 6 months. The primary safety endpoint will be the freedom from device-related serious adverse events at 6 months. The secondary endpoints will include the procedural success rate, time to first cannulation, patency rates, the rate of access-related interventions to maintain patency, the freedom from device-related serious adverse events and the rate of access site infections. Patients will be followed for 60 months. An exploratory Health Economic and Outcomes Research sub-study will determine potential additional benefits of the aXess graft to patients, health care institutions, and reimbursement programs.
DISCUSSION: The Pivotal study will examine the long-term performance and safety of the aXess Hemodialysis Graft and compare the outcome measures with historical data obtained with other graft types and autogenous AVFs. Potential advantages may include superior long-term patency rates and lower infection rates versus currently available AVGs and a shorter time to first cannulation compared to an autologous AVF. As such, the aXess Hemodialysis Graft may fulfill an unmet clinical need in the field of hemodialysis access.
Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
BACKGROUND: The CPG's updated recommendation is supported by buprenorphine's lower risk of overdose and misuse.(1) In comparison to full mu-opioid agonists, buprenorphine possesses a superior safety profile with respect to respiratory depression, even in non-dependent individuals, and fatal overdose, when not combined with other sedating medications.(2-5) Purpose/hypothesis: This project identifies prescribing trends of buprenorphine for chronic pain before and after implementing two pharmacy interventions. Procedures/data/observations: Patient charts were reviewed before and after removal of a drug authorization key in the electronic health record and development of an educational presentation for providers. In the pre-intervention group, 19 patients were included and 13 patients in the post-intervention group. Prescriptions for buprenorphine decreased by 31.5% from the pre-intervention to post-intervention period, but three new prescriptions were started after interventions.
CONCLUSIONS/APPLICATIONS: Adverse reactions were the cause of the decrease in prescriptions, most commonly nausea and vomiting. This data may be valuable to providers as they expand their knowledge about buprenorphine's analgesic use. This is a longitudinal project and identifying barriers that may limit prescribing of buprenorphine may be beneficial for future educational interventions.
The experimental group will consist of 20 participants (4 classical dancers, 6 Spanish dancers, 5 flamenco dancers and 5 contemporary dancers) who will not receive any strength training. They will be evaluated at the beginning and at the end of the study to compare the physical conditions of the participants of this group with those of the experimental group.
FIELD: freezing of red blood cells for long-time storage without affecting their properties. SUBSTANCE: method comprises step of centrifuging donor blood to separate red blood cells (erythrocytes) from plasma and thrombocytes until volume of globular mass of thrombocytes reaches at least 90%. Next red blood cells are transferred into freezing bag containing cosiethyl starch so that starch weight to volume of red blood cells is not more than 7%, preferably 6%. Device is made in form of frame adapted to accommodate bag filled with mixture to be frozen (liquid nitrogen). Frame consists of two arcuate perforated aluminium plates, flanges of which are bent in opposition to one another and represent guideways for planar-parallel displacement of plates. The latter are clamped together by clamping elements made of resilient material. EFFECT: method and device permit to store donor blood during long time periods for subsequent blood transfusion. 10 cl, 4 dwg
Pre-Screening - If the subject chooses to be pre-screened for this study they will be asked to fill out a study registration form and an oral habits/medical history form. They will be asked to sign an Informed Consent. The subject will then have their teeth and gums examined. At this visit, the investigator will assess whether or not the subject is a good candidate for the study. During the phone interview each subject was asked not to brush or floss their teeth and not to eat or drink anything other than water for 8 hours prior to the pre-screening visit (Visit 0). If the subject was compliant with these requests, oral samples will be collected at this pre-screening visit and will now be considered Visit 1 (Baseline). If not, they will be asked to return to the clinic for another visit and asked not to brush or floss their teeth and not to eat or drink anything other than water 8 hours prior to that appointment. This visit will then be consider Visit 1 (Baseline).

Visit 1 (Baseline) - The subject will have their medical and dental history reviewed. They will have their teeth and gums examined. Saliva and plaque will be collected. Each subject will be given a toothbrush and toothpaste and instructed to not use any other dental products. This will be considered the "washout" period.

Visit 2 - The subject will be asked to return the unused toothpaste. Their medical and dental history will be reviewed and they will have their teeth examined. Saliva and plaque will be collected at this visit. The subjects will then be randomly assigned (by chance, like the flip of a coin) to the group that will use a marketed fluoride-containing toothpaste or to the group that will use a marketed arginine containing toothpaste. The subject will also be instructed not to brush or floss their teeth or eat or drink anything other than water for 8 hours prior to your next appointment.

Visits 3, 4, and 5 - Subjects will not be allowed to brush or floss their teeth or eat or drink anything other than water 8 hours prior to these visits. Saliva and plaque will be collected. On the 5th visit subjects will be asked to return the unused toothpaste tube. At this time participation in this research study will end and they will be instructed to return to their regular oral hygiene regiments.
FIELD: biotechnology, biochemistry, foodstuffs. SUBSTANCE: method involves stages for culturing microorganism in medium that belongs to genus Ulkenia eliciting ability to produce docosahexaenoic and/or docosapentaenoic acids and extraction of lipids from culture. Method can involve additionally the stage for separation of docosahexaenoic acid and/or docosapentaenoic acid from lipids. The strain Ulkenia sp. SAM 2179 elicits ability to produce lipids comprising docosahexaenoic acid and docosapentaenoic acid. Foodstuffs and fodders containing lipids prepared by the described method elicit the biological activity and regulate the broad spectrum of physiological processes in body. EFFECT: improved preparing method, valuable properties of foodstuffs. 22 cl, 1 dwg, 6 tbl, 6 ex
The purpose of this pilot study is to provide preliminary data in support of the concept that training of the innate immune system occurs following immunization (2 doses ,3 months apart) with the Shingrix vaccine as compared to placebo (normal saline) in older adults residing in nursing homes. Two hundred nursing home residents, both men and women, aged \>65 years, who have not acquired COVID-19 (verified through a screening questionnaire and by both viral antigen and antibody testing at the screen and least one week before the first injection) will get two intramuscular injections containing either the Shingrix vaccine, and the other half, two injections containing a normal saline (placebo comparison) approximately three months apart. Blood samples are collected before the baseline injection (day zero), 1 day after the second injection (91 days post) and 1 month following the second injection (120 days). Weekly symptom checks and monthly antibody testing around day 180- will identify residents with COVID-19 and the severity of COVID-19 symptoms.

The primary outcome is the difference in immune cell capacity to produce type I interferon, interferon associated molecules, and proinflammatory mediators after receiving a 2 injection series of the Shingrix vaccine versus normal saline. Secondary outcomes include differences in hospitalization, pulmonary infections, and positive COVID-19 cases (via antibody testing on days 90, 120, and 180) in the Shingrix and normal saline groups. We anticipate that residents receiving the Shingrix vaccine will demonstrate signs of "trained" immunity compared to a control group receiving saline injections.
The pharmaceutical composition which foams in the intestine contains L-DOPA or a derivative thereof which is enzymatically split up into L-DOPA in vivo in humans, e.g. 3,4-diacetoxy-L-phenylalanine, and (a) an inert diluent, (b) an agent which releases carbon dioxide on exposure to organic acids, e.g. sodium bicarbonate, (c) an organic acid, e.g. tartaric acid, or its anhydride, and (d) a coating material which is resistant to gastric fluid and soluble in the intestine, e.g. hydroxypropylmethylcellulose phthalate. This prevents decomposition of L-DOPA in the stomach and its decarboxylation in the intestine, and virtually complete absorption in the small intestine is achieved without the occurrence of the side effects usual on oral administration. The pharmaceutical composition is preferably supplied in the form of tablets or capsules.
The present invention provides a method for counteracting preeclampsia, eclampsia of pregnancy and preterm labor in a pregnant female mammal treated by administering thereto calcitonin gene-related peptide (CGRP) or its analogues including CGRP/adrenomedullin or their peptide or receptor-based analogues, or in combination with a progestin, and with or without a nitric oxide substrate, or a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI 2  -mimetic, a thromboxane (TXA 2 ) inhibitor, a compound possessing TXA 2  -agonistic, and TXA 2  -inhibiting properties, a compound possessing TXA 2  -antagonistic and PGI 2  -mimetic activities, and a TXA 2  antagonist. CGRP, progesterone and some of the nitric oxide substrate and donor compounds are naturally occurring compounds. As such these agents do not have the same toxicity and allergy problems as the foreign substances that are currently used for similar purposes. During pregnancy uterine blood vessels and the uterine muscles are particularly sensitive to CGRP as well as nitric oxide. Therefore, one could administer a very small quantities of these drugs (i.e., intravenously, subcutaneous, or Implants), the effects are then seen mainly in the uterine muscle and blood vessels, namely increase the blood supply to the uteroplacental unit (hence nutrients and oxygen supply to the fetus through the improved placental circulation), and uterine muscular relaxation thereby ameliorate the signs and symptoms of preeclampsia, and eclampsia, and prevent preterm labor. At these dosages, virtually no systemic effects are induced, making CGRP (which is an endogenous natural product present in human body) extremely safe and effective.
PURPOSE:To obtain an active oxygen suppressing agent of a high safety, containing a hydrolysed substance of a mucilage from shellfishes. CONSTITUTION:A mucilage is obtained from shells after removing shells from a shellfish, by decantation, filtration, and centrifugation, etc., of them with or without pressurization. The intact mucilage or a precipitate obtained by a precipitation treatment, is subjected to a hydrolysis with an acid, a base or an enzyme to make it a low molecular weight substance. It is preferable to give a desalting treatment before or after the above hydrolysis treatment. The obtained hydrolyzed substance is used for an effective ingredient of an active oxygen suppressing agent. As to the shells as a source of the mucilage, those from Pteria breavialata, Mytilidae and Unionidae are preferable, but that of Pictada martensii for pearl cultivation is the most preferable. It is preferable to use an enzyme for the hydrolysis, since a required molecular weight and an objective peptide are easily obtainable with less byproducts due to decomposition.
Maternal immunologic mechanisms for tolerance are essential for a successful pregnancy because they prevent maladaptive immune responses to the placenta and semi-allogeneic fetus and promote fetal growth. Preeclampsia is a major global cause of fetal mortality and morbidity. It is characterized by new-onset hypertension and proteinuria that occurs at twenty weeks of pregnancy or later. Preeclampsia is defined by a rise in cytokines that are pro-inflammatory and antiangiogenic components in the fetoplacental unit and the vascular endothelium of pregnant women, as well as an excessive and increasing stimulation of the immune system. Crucially, inflammation can result in low birth weight and inadequate placental perfusion in neonates. Preeclampsia, which is ultimately connected to inflammatory responses, can be impacted by several immunological mechanisms. Our goal in this work was to compile the most recent research on the pathoimmunology of preeclampsia, including studies on angiogenic variables and, in particular, immunological components.
Currently, despite advancements in diagnostic and therapeutic modalities, osteomyelitis and prosthetic joint infection (PJI) continue to pose significant challenges for orthopaedic surgeons. These challenges are primarily attributed to the high degree of heterogeneity exhibited by these disorders, which are influenced by a combination of environmental and host factors. Recent research efforts have delved into the pathogenesis of osteomyelitis and PJI by investigating single nucleotide polymorphisms (SNPs). This review comprehensively summarizes the current evidence regarding the associations between SNPs and the predisposition to osteomyelitis and PJI across diverse populations. The findings suggest potential linkages between SNPs in genes such as IL-1, IL-6, IFN-γ, TNF-α, VDR, tPA, CTSG, COX-2, MMP1, SLC11A1, Bax, NOS2, and NLRP3 with the development of osteomyelitis. Furthermore, SNPs in genes like IL-1, IL-6, TNF-α, MBL, OPG, RANK, and GCSFR are implicated in susceptibility to PJI. However, it is noted that most of these studies are single-center reports, lacking in-depth mechanistic research. To gain a more profound understanding of the roles played by various SNPs in the development of osteomyelitis and PJI, future multi-center studies and fundamental investigations are deemed necessary.